Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy | Zendy

Pearse A. Keane | Zendy; Adnan Tufail | Zendy; Praveen J. Patel | Zendy

Open Access

Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy

Author(s) -

Pearse A. Keane,

Adnan Tufail,

Praveen J. Patel

Publication year - 2011

Publication title -

journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.818

H-Index - 40

eISSN - 2090-0058

pISSN - 2090-004X

DOI - 10.1155/2011/752543

Subject(s) - medicine , ranibizumab , macular degeneration , discontinuation , bevacizumab , ophthalmology , clinical practice , vascular endothelial growth factor , maintenance therapy , vegf receptors , physical therapy , chemotherapy

Neovascular age-related macular degeneration (AMD) is a leading cause of irreversible visual loss in elderly populations. In recent years, pharmacological inhibition of vascular endothelial growth factor (VEGF), via intravitreal injection of ranibizumab (Lucentis) or bevacizumab (Avastin), has offered the first opportunity to improve visual outcomes in patients diagnosed with this disorder. In this paper, we provide recommendations on how bevacizumab and ranibizumab may be best applied in current clinical practice, with an emphasis on their underlying pharmacology and efficacy. In addition, we review current guidelines for the initiation, maintenance, and discontinuation of anti-VEGF therapies, as well as emerging treatment strategies and future directions in the field.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research